|
Caffeine related disorders
|
0.090 |
Biomarker
|
group |
BEFREE |
A sensitive, specific, and fast ultra-high performance liquid chromatography/tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for determination of caffeine (probe of CYP1A2), tolbutamide (probe of CYP2C9), dextromethorphan (probe of CYP2D6), and alprazolam (probe of CYP3A4/5) in human serum.
|
31744669 |
2020 |
|
Caffeine related disorders
|
0.090 |
Biomarker
|
group |
BEFREE |
The ratios of geometric least squares mean (90% confidence interval) for the area under the concentration-time curve from time zero to the last quantifiable concentration in the presence/absence of tivantinib were 0.97 (0.89-1.05) for caffeine, 0.88 (0.76-1.02) for S-warfarin, 0.89 (0.60-1.31) for omeprazole, 0.83 (0.67-1.02) for midazolam, and 0.69 (0.51-0.94) for digoxin.
|
28865153 |
2018 |
|
Caffeine related disorders
|
0.090 |
GeneticVariation
|
group |
BEFREE |
The primary objective is to determine and compare major CYP450 activities in patients with T2DM versus non-diabetic subjects by dosing in plasma and urine probe drug substrates and metabolites following the oral administration of a drug cocktail: caffeine (CYP1A2), bupropion (CYP2B6), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), chlorzoxazone (CYP2E1) and midazolam (CYP3A4/5).
|
29439084 |
2018 |
|
Caffeine related disorders
|
0.090 |
GeneticVariation
|
group |
BEFREE |
Therefore, we studied the effect of short-term fasting on protein binding of five commonly used probe drugs [caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), omeprazole (CYP2C19) and S-warfarin (CYP2C9)].
|
28929443 |
2018 |
|
Caffeine related disorders
|
0.090 |
Biomarker
|
group |
BEFREE |
The OATP1B1 (pitavastatin) and five P450 probe substrates, caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A) and their metabolites were extracted from human plasma (50 µL) using methanol.
|
30004443 |
2018 |
|
Caffeine related disorders
|
0.090 |
Biomarker
|
group |
BEFREE |
The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively.
|
29550976 |
2018 |
|
Caffeine related disorders
|
0.090 |
Biomarker
|
group |
BEFREE |
The probes for testing CYP1A2 are phenacetin and caffeine while for CYP2C9 tolbutamide.
|
28992765 |
2018 |
|
Caffeine related disorders
|
0.090 |
Biomarker
|
group |
BEFREE |
In a randomized, controlled, crossover trial, 12 healthy subjects received a single administration of a cytochrome P450 (CYP) probe cocktail, consisting of caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), omeprazole (CYP2C19) and warfarin (CYP2C9), on four occasions: an oral (1) and intravenous (2) administration after an overnight fast (control) and an oral (3) and intravenous (4) administration after 36 h of fasting.
|
28229374 |
2017 |
|
Caffeine related disorders
|
0.090 |
Biomarker
|
group |
BEFREE |
OCA showed no substantial suppression/inhibition of S-warfarin, digoxin, and dextromethorphan and weak interactions with caffeine, omeprazole, rosuvastatin, and midazolam.
|
28808886 |
2017 |